Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2017

View Archived Issues

Psyadon Pharmaceuticals reports positive findings from study of ecopipam in Tourette's syndrome

EC grants new orphan drug designation to Corbus' JBT-101

Biogen and Forward Pharma sign settlement and license agreement

Protagonist Therapeutics begins phase IIb study of oral peptide for ulcerative colitis

FDA grants fast track designation to Trappsol Cyclo for Niemann-Pick disease type C

GeoVax and Georgia State University sign research collaboration agreement for HBV vaccine

Phase III study of metadoxine extended release in ADHD does not meet primary endpoint

L-Moses is a novel PCAF bromodomain chemical probe showing promise in vitro

Phase Ib results for alpelisib plus letrozole in patients with ER+ breast cancer

Tesaro opens expanded access program in U.S. for niraparib

Anti-HER2 DC1 vaccination is a safe and immunogenic in HER2+ patients

CE mark for Chembio's DPP HIV-Syphilis combination assay

Merck & Co. discloses novel PI3Kdelta inhibtors

Nimbus Therapeutics patents IRAK-4 inhibitors

GSK-598809 restores reward deficits in substance dependence

Wockhardt presents novel bicyclic antibacterial activity enhancers

GlaxoSmithKline describes new indoleamine 2,3-dioxygenase 1 inhibitors

Sato Pharmaceutical obtains rights to SB-204 in Japan

FDA awards new orphan drug designation to Remedy's Cirara

Orion presents novel bromodomain-containing protein 4 inhibitors

Celsion reports data from fourth cohort of OVATION study

Protagen and German National Center for Tumor Diseases enter biomarker collaboration

Cancer Genetics and Lantern Pharma enter strategic collaboration

Pulmatrix's PUR-1900 wins FDA QIDP designation

XG-102 is noninferior to dexamethasone for the treatment of postoperative ocular inflammation

Full phase I study results reported for AADvac1 vaccine in patients with Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...